Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion type Assertion NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_head.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion description "[Moreover, dominant negative cross talk between ectopic wild-type p53 and recently identified dominant p53 mutants and splice variants of p63 and p73--which are frequently overexpressed in ovarian cancers--could seriously compromise the effectiveness of p53 gene therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_provenance.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion evidence source_evidence_literature NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_provenance.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion SIO_000772 12850192 NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_provenance.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion wasDerivedFrom befree-20150227 NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_provenance.
- NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_assertion wasGeneratedBy ECO_0000203 NP674957.RAbj9uTAJWnkDpL_0CpI3w5H__M17QZTisb0fiWZEqI98130_provenance.